Medical Prevention and Treatment of Bone Metastases
- 28 September 2018
- book chapter
- other
- Published by Wiley
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerThe New England Journal of Medicine, 2013
- Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate CancerEuropean Urology, 2012
- Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trialThe Lancet, 2012
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyThe Lancet, 2011
- Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind StudyJournal of Clinical Oncology, 2010
- Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast CancerThe New England Journal of Medicine, 2009
- Bone markers and their prognostic value in metastatic bone disease: Clinical evidence and future directionsCancer Treatment Reviews, 2008
- Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the Bisphosphonate Zoledronic AcidJournal of Clinical Oncology, 2005
- Markers of Bone Remodeling in Metastatic Bone DiseaseJournal of Clinical Endocrinology & Metabolism, 2003
- Osteoclast differentiation and activationNature, 2003